Pharma Journalist -

Gilead Sciences, Inc. announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...

PerkinElmer, Inc. and Honeycomb Biotechnologies, Inc., announced the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis. The HIVE…
Read More...

Exelixis, Inc. and STORM Therapeutics announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug…
Read More...

Supernus Pharmaceuticals, Inc. and Adamas Pharmaceuticals, Inc. announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an…
Read More...

Intellia Therapeutics, Inc. a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and…
Read More...

Pacira BioSciences, Inc. the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive…
Read More...

CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced the strategic decision to…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) as adjuvant treatment, following surgery and platinum-based chemotherapy, for adults…
Read More...

Silence Therapeutics plc a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with…
Read More...

Johnson & Johnson announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend…
Read More...